• Capstone Therapeutics posted a net loss of $1.92 million for the quarter ended March 31, 2026, widening 11% from a year earlier.
• Net sales rose to $12.64 million, up 60%, while gross profit climbed to $2.97 million, up 124%.
• Gross margin improved to 23.5% from 16.8%, reflecting gains in the TotalStone segment and the addition of Carolina Stone, which carried a gross margin of about 37.8%.
• Operating loss widened to $1.5 million as selling, general and administrative expenses increased to $4.47 million, up 62%, while interest and other expense deepened to $892,000, up 197%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-017870), on May 20, 2026, and is solely responsible for the information contained therein.